FluGen Inc

About

FluGen Inc is a clinical-stage biopharmaceutical company based in Madison, Wisconsin, transforming vaccine efficacy in respiratory diseases through innovative vaccine manufacturing and development. Founded in 2007, the company specializes in developing advanced influenza vaccines using their proprietary M2SR Vaccine Platform technology. This revolutionary supra-seasonal, live, single-replication, intranasal flu vaccine has the potential to transform the five billion dollar annual influenza market by addressing critical unmet needs including consistent efficacy, annual virus drift, and viral shedding. Unlike standard flu vaccines, M2SR stimulates mucosal, humoral, and cellular immunity through a unique manufacturing process where influenza viruses undergo a controlled single round of viral replication. FluGen has successfully raised over 40 million dollars in capital and completed multiple human clinical trials with M2SR, including NIH-funded studies in adults up to age 85 and Department of Defense-funded trials in older adults. The company is advancing dual-defense vaccine capabilities, developing combination platforms that protect against both influenza and COVID-19. With ongoing Phase 1b clinical trials demonstrating promising safety and immunogenicity results across pediatric and geriatric populations, FluGen continues to advance manufacturing capabilities for commercial-scale production of next-generation respiratory disease vaccines.